IGI reports phase 1 results of ISB 2001 trispecific antibody in relapsed or refractory multiple… EP News Bureau Jun 4, 2025 TRIgnite-1 study shows 79 per cent response rate and no dose-limiting toxicities in early-stage trial of BCMA × CD38 × CD3…
Ichnos Glenmark Innovation to present phase 1 study data on Trispecific Antibody ISB 2001 at ASH… EP News Bureau Nov 6, 2024 Early results show promising response rates and safety profile for ISB 2001 in relapsed/refractory multiple myeloma patients
Glenmark and Ichnos launch Ichnos Glenmark Innovation to accelerate new drug discovery in cancer… EP News Bureau Jan 30, 2024 The newly formed IGI features a pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia…
